Multi-Site Trial of Tirzepatide for Smoking Cessation
NCT07602699 on ClinicalTrials.gov · last registry update 2026-07-17
An unusually large phase 2: 300 participants, more than double the 114 typical for the stage. Due to report March 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: 7-day point prevalence abstinence. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- University of Southern California
- Sponsor type
- Other
- Enrollment
- 300
- Started
- 2026-06-05
- Primary completion
- 2028-03 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
7-day point prevalence abstinence
Conditions studied
Smoking Cessation · Smoking Behaviors
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.